Skip to main content

Pharmaceutical Needs Assessment 2018-2021 Bury Council

From 1st April 2013, Bury Health and Wellbeing Board (HWB) has a statutory responsibility to publish and keep up-to-date a statement of the needs for pharmaceutical services for the population in its area, referred to as a 'pharmaceutical needs assessment' (PNA). The PNA aims to identify whether current pharmaceutical service provision meets the needs of the population. The PNA considers whether there are any gaps to service delivery.

The PNA may be used to inform commissioners such as clinical commissioning groups (CCG) and local authorities (LA), of the current provision of pharmaceutical services and where there are any gaps in relation to the local health priorities. Where such gaps are not met by NHS England, these gaps may then be considered by those organisations.

The PNA will be used by NHS England in its determination as to whether to approve applications to join the pharmaceutical list under The National Health Service (Pharmaceutical and Local Pharmaceutical Services) Regulations 2013. The relevant NHS England area team will then review the application and decide if the application meets the criteria for approval, as set out in the Regulations. When making the decision NHS England is required to refer to the local PNA.

Bury has a population of 188,700 (mid-2016 population estimate). This is estimated to increase by over 6.2% to 201,200 by the early 2030's, mostly due to an increase in the over 65's.

Map produced by Medicines Optimisation Team (GM), NHS North West Commissioning Support Unit, St James House, Pendleton Way, Salford, M6 5FW.
Greater Manchester Shared Services on behalf of Bury Council, the NHS England Greater Manchester Area Team (GMAT), Bury Clinical Commissioning Group (CCG) and the Local Pharmaceutical Committee (LPC).
Number of Pages
Date Published
Published by
Performance & Intelligence (PI.SDU) Bury Council
Back to top